drugset / Trial / NCT01759446

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

NCT01759446

Phase 2 Completed 44 enrolled Acura Pharmaceuticals Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when crushed and administered intranasally to non dependent, recreational opioid users.

Timeline

Start
2013-02
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 325 mg Intranasal
Comparator hydrocodone bitartrate Unknown 10 mg Intranasal